




FIG. 1



# Dose-Dependent Increase in Peak Flow Velocity Caused by CVT-3146




Figure 2

# CVT-3146 and Coronary Flow Velocity

## *Duration of Effect:*

Duration $\geq 2.5$ Baseline	
Dose (n)	Mean $\pm$ SEM
10 $\mu\text{g}$ (4)	0
30 $\mu\text{g}$ (4)	0
100 $\mu\text{g}$ (3)	0.2 $\pm$ 0.2 minutes
300 $\mu\text{g}$ (4)	2.2 $\pm$ 1.3 minutes
400 $\mu\text{g}$ (8)	2.8 $\pm$ 0.8 minutes
500 $\mu\text{g}$ (4)	2.9 $\pm$ 1.3 minutes

**Figure 3**

# Time Course of APV Ratio (CVT-3146 400 $\mu$ g)





Figure 4

# Time Course of Heart Rate (CVT-3146 400 $\mu$ g)



# Time Course of Blood Pressure (CVT-3146 400 µg)




Figure 6

# All Drug-Related Adverse Events Were Mild and Transient

Adverse Event	All Doses	
	(n = 36)	400 µg (n = 9)
chest discomfort	3	3
increased heart rate	3	1
hypotension	2	2
flushing	2	1
shortness of breath	2	0
funny taste in mouth	1	0
sensation in mouth, sinus, and chest	1	0
headache	1	0
tingling in hands	1	1
heart racing	1	1
bradycardia	1	1
lightheadedness	1	1
cough	1	0
nausea and vomiting	1	0

7/17

Figure 7

Figure 8

# Mean CVT-3146 Plasma Concentration in Healthy Male Volunteers - Supine Position






Figure 9




Figure 10




Figure 11




Figure 12




Figure 13




Figure 14







Figure 15



**Figure 16****Figure 17**






Figure 18